Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001880010 | SCV002246632 | uncertain significance | Noonan syndrome 8 | 2024-04-25 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 126 of the RIT1 protein (p.Asp126Asn). This variant is present in population databases (rs760053864, gnomAD 0.004%). This variant has not been reported in the literature in individuals affected with RIT1-related conditions. ClinVar contains an entry for this variant (Variation ID: 981606). Advanced modeling performed at Invitae incorporating data from internal and/or published experimental studies (Invitae) indicates that this missense variant is not expected to disrupt RIT1 function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ce |
RCV003405469 | SCV004124972 | uncertain significance | not provided | 2022-07-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004035388 | SCV005014280 | uncertain significance | Cardiovascular phenotype | 2024-01-22 | criteria provided, single submitter | clinical testing | The c.376G>A (p.D126N) alteration is located in exon 5 (coding exon 4) of the RIT1 gene. This alteration results from a G to A substitution at nucleotide position 376, causing the aspartic acid (D) at amino acid position 126 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Service de Génétique Moléculaire, |
RCV001261145 | SCV001438554 | uncertain significance | Cardio-facio-cutaneous syndrome | no assertion criteria provided | clinical testing |